Anemia in the Treatment of Hepatitis C Virus Infection

Clinical Infectious Diseases

Volumn 37, Issue SUPPL. 4, 2003, Pages

  Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ANEMIA; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; PRIORITY JOURNAL; REDUCTION; REVIEW; SIDE EFFECT;

ANEMIA; ANTIVIRAL AGENTS; EPOETIN ALFA; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 0242573461     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376911     Document Type: Review

References (25)

1. Lawrence SP. Advances in the treatment of hepatitis C. Adv Intern Med 2000; 45:65-105.
2. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234:384-94.
3. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(5 Suppl 1):30-4.
4. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107(6B):79S-84S.
5. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
6. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
8. Boyer JL, Chang EB, Collyar DE, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36(5 Suppl 1):S3-20.
9. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
10. Lindsay K, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
11. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40kd) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [abstract 1]. J Hepatol 2002; 36(Suppl 1):3.
12. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine MD. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000; 14:1857-8.
13. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-7.
14. Kostman JR, Smith JJ, Giffen CA, Frost KR. Interferon alfa-2b/ribavirin combination therapy in HIV/HCV co-infected persons: results of a multicenter randomized, double-blind, controlled trial [abstract]. Hepatology 2001; 34(4 Pt 2):330A.
15. Chung R, Anderson J, Alston B, et al. A randomized controlled trial of pegylated interferon alfa-2a with ribavirin versus interferon alfa-2a with ribavirin for the treatment of chronic HCV in HIV coinfection: ACTG A5071 [abstract LB15]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle, WA), 2002.
16. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961-6.
17. Intron A (Interferon alfa-2b, recombinant for injection) prescribing information. Kenilworth, NJ: Schering, January 2000.
18. Rebetron (combination therapy containing Rebetol [ribavirin, USP] capsules and Intron A [interferon alfa-2b, recombinant injection]) prescribing information. Kenilworth, NJ: Schering, January 2001.
19. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-7.
20. Rendo P, Rosso A, Gómez F, et al. Anemia in patients with chronic hepatitis C treated with ribavirin and interferon [abstract C181]. Antiviral Ther 2000;5(Suppl 1):C96.
21. Sulkowski M, Wasserman R, Brooks LJ, Ball L, Gish RG. Changes in hemoglobin during interferon alfa-2b plus ribavirin combination therapy for chronic HCV infection. J Viral Hepatitis (in press).
22. Weisz KB, Braun JF, Dieterich DT, et al. Erythropoietin use for ribavirin/interferon-induced anemia in hepatitis C patients [abstract H-156]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA). Washington, DC: American Society for Microbiology, 1998:359.
23. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α. Am J Gastroenterol 2001; 96:2802-4.
24. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alpha. Am J Gastroenterol (in press).
25. Dieterich D, Weisz K, Goldman D, Talal A, Malicdem L, Markatou M. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV-coinfected patients [abstract H-105]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, 1999:415.